95 results found.

Parkinson's Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Positron Emission Tomography (PET) Scanning in Dopamine Disorders: Parkinson's Disease and Schizophrenia.

Schizophrenia, Smoking Cessation, or Nicotine Abuse Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 62 years.
- Brain Circuits in Schizophrenia and Smoking.

Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, or Maj Clinical Trial using Ending Self Stigma (ESS); Health and Wellness Group

Department of Veterans Affairs - Recruiting 18 years to 80 years.
- Reducing Internalized Stigma In People With Serious Mental Illness.
Ending Self Stigma (ESS); Health and Wellness Group

Schizophrenia, or Schizoaffective Disorder Clinical Trial using Cognitive Enhancement Therapy; Enriched Supportive Therapy

Beth Israel Deaconess Medical Center - Recruiting 18 years to 35 years.
- Brain Imaging, Cognitive Enhancement and Early Schizophrenia.
Cognitive Enhancement Therapy; Enriched Supportive Therapy

Schizophrenia Clinical Trial using levodopa/carbidopa (generic version of Sinemet)

Centre for Addiction and Mental Health - Recruiting 18 years to 55 years.
- Augmentation of Antipsychotics With L-Dopa (Sinemet).
levodopa/carbidopa (generic version of Sinemet)

Schizophrenia Clinical Trial

Genentech - Recruiting 18 years or older.
- A Prospective, Non-Interventional Registry of Diverse Patients With Schizophrenia Across the Disease Spectrum in Usual Care Settings: Course of Disease, Treatments, and Burden of Illness.

Schizophrenia, Schizoaffective Disorder, or Schizophreniform Diso Clinical Trial using TAU

Pakistan Institute of Learning and Living - Recruiting 18 years to 35 years.
- A Randomised Double Blind Placebo Controlled 12 Week Trial of Methotrexate Added to Treatment As Usual in Early Schizophrenia.
TAU

Schizophrenia, or Psychotic Disorder Clinical Trial using CTI-TS

Columbia University - Recruiting 21 years to 65 years.
- A Pilot Multi-center Randomized Controlled Trial of Critical Time Intervention - Task Shifting (CTI-TS) Versus Usual Care for People With Psychotic Disorders.
CTI-TS

Bipolar Disorder, Depression, Anxiety Disorders, Schizophrenia, T Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Brain Procurement for the Human Brain Collection Core.

Cognitive Behavioral Social Skills Training + Oxytocin, or Cognit Clinical Trial using CBSST with Oxytocin; CBSST with Placebo

University of Maryland - Recruiting 18 years to 55 years.
- Combined Oxytocin and CBSST for Social Function in People With Schizophrenia.
CBSST with Oxytocin; CBSST with Placebo

Schizophrenia Clinical Trial using Asenapine Sublingual Tablets 10 mg

Amneal Pharmaceuticals, LLC - Recruiting 18 years to 65 years.
- A Multicentric, Open Label, Randomized, Balanced, Two Treatment, Three Period, Three Sequence, Crossover, Multiple Dose, Steady State Bioequivalence Study of Asenapine Sublingual Tablets, 10 mg Manufactured by AMNEAL PHARMACEUTICALS, USA With Reference Product SAPHRISr (Asenapine) Sublingual Tablets, 10 mg Manufactured by Catalent UK Swindon Zydis Ltd., Blagrove, Swindon, Wiltshire, SN5 8RU, UK; Distributed by Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, 08889, USA in Adult Human Male & Female Patients Under Fasting Condition..
Asenapine Sublingual Tablets 10 mg

Schizophrenia Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- .

Schizophrenia Clinical Trial using Brexpiprazole

H. Lundbeck A/S - Recruiting 18 years to 65 years.
- Interventional, Open-label, Flexible-dose Extension Study of Brexpiprazole in Patients With Schizophrenia.
Brexpiprazole

Schizophrenia Clinical Trial using ITI-214 Dose A; ITI-214 Dose B; ITI-214 Dose C; ITI-214 Dose D (Elderly); Placebo; ITI-214 Dose E; ITI-214 Dose F; ITI-214 Dose G; ITI-214 Dose H

Takeda - Recruiting 18 years or older.
- A Phase 1, Randomized, Placebo- Controlled, Double-Blind Safety, Tolerability, Pharmacokinetic, and Exploratory Pharmacodynamic Study in Healthy Subjects and Subjects With Stable Schizophrenia After Multiple Doses of ITI-214.
ITI-214 Dose A; ITI-214 Dose B; ITI-214 Dose C; ITI-214 Dose D (Elderly); Placebo; ITI-214 Dose E; ITI-214 Dose F; ITI-214 Dose G; ITI-214 Dose H

Auditory Verbal Hallucinations, or Schizophrenia Clinical Trial using tDCS

Charite University, Berlin, Germany - Recruiting 18 years to 80 years.
- The Mechanism of Non-invasive Brain Stimulation for Therapy of Chronic Auditory Verbal Hallucinations in Schizophrenia.
tDCS

Schizophrenia Clinical Trial using Paliperidone extended-release; Risperidone immediate-release

Johnson & Johnson Taiwan Ltd - Recruiting 20 years to 60 years.
- A Randomized, Open-Label, Study To Evaluate The Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Selected Cognitive Domains in Clinically Stable Subjects With Schizophrenia.
Paliperidone extended-release; Risperidone immediate-release

Psychosis, or Schizophrenia Clinical Trial using Early Detection (ED); Usual Detection

Yale University - Recruiting 16 years to 35 years.
- STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S..
Early Detection (ED); Usual Detection

Schizophrenia, Schizoaffective Disorder, or Auditory Hallucinatio Clinical Trial using tDCS; tACS; Sham stimulation

University of North Carolina, Chapel Hill - Recruiting 18 years or older.
- Clinical Trial to Assess Transcranial Current Stimulation as a Treatment for Medication Refractory Auditory Hallucinations in Schizophrenia.
tDCS; tACS; Sham stimulation

Schizophrenia Clinical Trial using Asenapine 5 mg; Asenapine 10 mg; Placebo

Merck Sharp & Dohme Corp. - Recruiting 20 years to 64 years.
- A Multicenter, Randomized, Double-blind, Fixed-dose, 6-week Trial of the Efficacy and Safety of Asenapine Compared With Placebo in Subjects With an Acute Exacerbation of Schizophrenia (Phase 3; P06124).
Asenapine 5 mg; Asenapine 10 mg; Placebo

Schizoaffective Disorder, or Schizophrenia Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 90 years.
- Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography.

Healthy, or Schizophrenia Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 6 years or older.
- Biochemical, Physiological, and Psychological Measures in Normal Controls and Relatives of Psychiatric Patients.

Childhood Onset Psychotic Disorders, Schizophrenia, Psychosis, or Clinical Trial using Electrical Polarization

National Institutes of Health Clinical Center (CC) - Recruiting 10 years or older.
- Safety of Transcranial Direct Current Brain Stimulation (TDCS) for Improvement of Psychotic Symptoms and Cognitive Functioning in Childhood Onset Schizophrenia (COS).
Electrical Polarization

Schizophrenia Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 55 years.
- Default Network Dysfunction Underlying Visuospatial Attention Deficits in Schizophrenia.

Psychotic Disorder, Schizoaffective Disorder, or Schizophrenia Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Neurobiological Investigation of Patients With Schizophrenia Spectrum Disorders and Their Siblings.

Schizophrenia Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 55 years.
- Dopamine Function and Reward Processing In Schizophrenia.

Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Ps Clinical Trial

University of Arizona - Recruiting 18 years to 75 years.
- Social Cognition in Longstanding Psychosis.

Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Ps Clinical Trial using Group Cognitive Behavioral Therapy; Multifamily Group Psychoeducation

University of Arizona - Recruiting 18 years to 35 years.
- Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis.
Group Cognitive Behavioral Therapy; Multifamily Group Psychoeducation

Schizophrenia Clinical Trial using Lurasidone

Northwestern University - Recruiting 18 years to 60 years.
- High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia.
Lurasidone

Schizophrenia Clinical Trial using No intervention

Janssen-Cilag International NV - Recruiting 18 years or older.
- HOSPItal Use of Paliperidone Palmitate - A Prospective Non-Interventional Study.
No intervention

Schizophrenia, or Impaired Cognition Clinical Trial using EVP-6124

EnVivo Pharmaceuticals, Inc. - Recruiting 18 years to 50 years.
- A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to Two Doses of EVP-6124, an Alpha-7 Nicotinic Acetylcholine Receptor Agonist, as an Adjunctive Pro-cognitive Treatment in Subjects With Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy.
EVP-6124

Schizophrenia Clinical Trial using Asenapine; Placebo Asenapine; Olanzapine; Placebo Olanzapine

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Multicenter, Randomized, Double-Blind, Fixed-Dose, 6-Week Trial of the Efficacy and Safety of Asenapine Compared With Placebo Using Olanzapine as an Active Control in Subjects With an Acute Exacerbation of Schizophrenia.
Asenapine; Placebo Asenapine; Olanzapine; Placebo Olanzapine

Schizophrenia Clinical Trial using No intervention

Janssen Korea, Ltd., Korea - Recruiting N/A or older.
- Korea Post-Marketing Surveillance of Invega Sustenna.
No intervention

Schizophrenia, or Impaired Cognition Clinical Trial using EVP-6124; Placebo

EnVivo Pharmaceuticals, Inc. - Recruiting 18 years to 50 years.
- A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy.
EVP-6124; Placebo

Schizophrenia, or Impaired Cognition Clinical Trial using EVP-6124; Placebo

EnVivo Pharmaceuticals, Inc. - Recruiting 18 years to 50 years.
- A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy.
EVP-6124; Placebo

Schizophrenia Clinical Trial using bitopertin [RO4917838]; Placebo

Hoffmann-La Roche - Recruiting 18 years or older.
- Phase III, Multi-center, Randomized, 12-week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 40-week Double-blind, Parallel-group, Placebo-controlled Treatment Period..
bitopertin [RO4917838]; Placebo

Schizophrenia Clinical Trial using Fingolimod; placebo

Indiana University - Recruiting 18 years to 65 years.
- Safety and Efficacy of Fingolimod in Schizophrenia Patients Who Have Suboptimal Responses to Antipsychotic Drug Treatment.
Fingolimod; placebo

Psychosis, Schizophrenia, Schizoaffective Disorder, or Schizophre Clinical Trial using Metacognitive Training (MCT); Cognitive Remediation (CR)

University of British Columbia - Recruiting 19 years to 55 years.
- Functional Brain Networks Underlying Non-pharmaceutical Interventions for Psychosis..
Metacognitive Training (MCT); Cognitive Remediation (CR)

Schizophrenia Clinical Trial using Shared Decision Making

Yokohama City University - Recruiting 16 years to 65 years.
- Shared Decision Making for Patients With First-admission Schizophrenia: a Randomized Controlled Trial.
Shared Decision Making

Schizophrenia, or Schizoaffective Disorder Clinical Trial using LY03004

Luye Pharma Group Ltd. - Recruiting 18 years to 65 years.
- An Open-Label, Single Ascending Dose Pharmacokinetic and Safety Study of LY03004 Following Escalating Single Intramuscular Injection in Stable Patients With Schizophrenia or Schizoaffective Disorder.
LY03004

Schizophrenia Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A Non-Interventional Prospective Cohort Study of Patients With Persistent Symptoms of Schizophrenia to Describe The Course and Burden of Illness.

Schizophrenia, or Schizoaffective Disorder Clinical Trial using DMXB-A-SR; Placebo

University of Colorado, Denver - Recruiting 18 years to 65 years.
- Nicotinic Receptors and Schizophrenia: Phase II.
DMXB-A-SR; Placebo

Schizophrenia, or Bipolar Disorder Clinical Trial using Lurasidone

Sunovion - Recruiting N/A or older.
- A Long-term, Multicenter, Open-Label, Flexible Dose Continuation Study in Subjects Who Have Completed a Prior Lurasidone Study.
Lurasidone

Schizophrenia, or Austism Clinical Trial using Lurasidone 20, 40, 60, 80 mg, flexibly dosed

Sunovion - Recruiting 6 years to 17 years.
- A 104-Week, Flexible-Dose, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Effectiveness of Lurasidone in Pediatric Subjects With Schizophrenia and Subjects With Irritability Associated With Autistic Disorder.
Lurasidone 20, 40, 60, 80 mg, flexibly dosed

Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorde Clinical Trial using Risperidone; Omega-3 capsules; Amber 50/50 Soybean/Corn Placebo

North Shore Long Island Jewish Health System - Recruiting 15 years to 40 years.
- Detecting Which Patients With Schizophrenia Will Improve With Omega-3 Treatment.
Risperidone; Omega-3 capsules; Amber 50/50 Soybean/Corn Placebo

Schizophrenia Clinical Trial using Varenicline; Placebo

Centre for Addiction and Mental Health - Recruiting 18 years to 55 years.
- Effects of Varenicline on Cortical Neuroplasticity and Working Memory in Patients With Schizophrenia and Healthy Controls.
Varenicline; Placebo

Schizophrenia Clinical Trial using bitopertin [RO4917838]; Placebo

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period..
bitopertin [RO4917838]; Placebo

Schizophrenia Clinical Trial using bitopertin [RO4917838]; Placebo

Hoffmann-La Roche - Recruiting 18 years or older.
- Phase III, Multi-center, Randomized, 12-week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 40-week Double-blind, Parallel-group, Placebo-controlled Treatment Period..
bitopertin [RO4917838]; Placebo

Schizophrenia Clinical Trial using RO5545965; Placebo; risperidone

Hoffmann-La Roche - Recruiting 18 years to 60 years.
- A SINGLE-CENTER, RANDOMIZED, INVESTIGATOR/SUBJECT-BLIND, MULTIPLE-DOSE, PLACEBO-CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF RO5545965 IN PATIENTS WITH SCHIZOPHRENIA ON RISPERIDONE..
RO5545965; Placebo; risperidone

Schizophrenia Clinical Trial using Lurasidone; Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2; Placebo

Sunovion - Recruiting 18 years to 75 years.
- A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Low-dose Lurasidone in Acutely Psychotic Subjects With Schizophrenia.
Lurasidone; Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2; Placebo

Schizophrenia Clinical Trial using Lurasidone 40 mg; Lurasidone 80 mg; Placebo 40 or 80 mg

Sunovion - Recruiting 13 years to 17 years.
- A 6-Week Randomized, Parallel, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study To Evaluate The Efficacy and Safety of Lurasidone in Adolescent Subjects With Schizophrenia.
Lurasidone 40 mg; Lurasidone 80 mg; Placebo 40 or 80 mg

Schizophrenia Clinical Trial using Iloperidone; Placebo

Novartis - Recruiting 18 years to 65 years.
- A Multicenter, Randomized, Double-blind Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Double Iloperiodone (Fanapt) or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weks of Open-label Extension.
Iloperidone; Placebo

Schizophrenia, or Schizoaffective Disorder Clinical Trial using Olanzapine; Amisulpride; Olanzapine and Amisulpride

Heinrich-Heine University, Duesseldorf - Recruiting 18 years to 65 years.
- A Randomized Double-blind Controlled Trial to Assess the Benefits of Olanzapine and Amisulpride Combination Treatment in Acutely Ill Schizophrenia Patients. - COMBINE.
Olanzapine; Amisulpride; Olanzapine and Amisulpride

Schizophrenia, or Bipolar Disorder Clinical Trial using Integrated Care with Assertive community treatment with hometreatment, n=120; SC

Universit„tsklinikum Hamburg-Eppendorf - Recruiting 12 years to 29 years.
- Integrated Care in Early Psychosis (ICEP Study): a 12-month Quasi Experimental Study With Historic Control Group.
Integrated Care with Assertive community treatment with hometreatment, n=120; SC

Schizophrenia, Schizoaffective Disorder, or Schizophreniform Diso Clinical Trial using Raloxifene hydrochloride; Lactose Capsules

The Alfred - Recruiting 18 years to 70 years.
- Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia?.
Raloxifene hydrochloride; Lactose Capsules

Schizophrenia, Schizoaffective Disorder, or Schizophreniform Diso Clinical Trial using Raloxifene Hydrochloride; Placebo

The Alfred - Recruiting 18 years to 45 years.
- A Randomised Controlled Trial of Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men?.
Raloxifene Hydrochloride; Placebo

Schizophrenia, or Bipolar Disorder Clinical Trial using CBT2go; Smartphone

University of California, San Diego - Recruiting 18 years to 55 years.
- Real-Time Mobile Cognitive Behavioral Intervention for Serious Mental Illness.
CBT2go; Smartphone

Schizophrenia, Schizoaffective Disorder, or Schizophreniform Diso Clinical Trial using Olanzapine or amisulpride

Technische Universit„t Mnchen - Recruiting 18 years to 65 years.
- The Switch Study - Efficacy of Early Antipsychotic Switch Versus Maintenance in Patients With Schizophrenia Poorly Responding to Two Weeks of Antipsychotic Treatment.
Olanzapine or amisulpride

Schizophrenia, Schizophreniform Disorder, or Schizoaffective Diso Clinical Trial

New York University School of Medicine - Recruiting 16 years to 40 years.
- Biomarkers in First Episode Schizophrenia.

Schizophrenia, Psychosis, or First Episode Psychosis Clinical Trial using Risperidone

University of Alabama at Birmingham - Recruiting 17 years to 35 years.
- Glutamate, Brain Connectivity and Duration of Untreated Psychosis.
Risperidone

Schizophrenia, or Schizoaffective Disorder Clinical Trial using Repetitive Transcranial Magnetic Stimulation

Centre for Addiction and Mental Health - Recruiting 18 years to 59 years.
- Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Working Memory Deficits in Schizophrenia and Effects on Brain Structure.
Repetitive Transcranial Magnetic Stimulation

Schizophrenia Clinical Trial using Tolcapone

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 50 years.
- Randomized, Double-Blinded, Placebo Controlled Study of the Effects of Tolcapone and Entacapone on Cognitive Function in Patients With Schizophrenia and Normal Controls Based on COMT Genotype.
Tolcapone

Schizophrenia Clinical Trial using MP-214 low dose; MP-214 middle dose; MP-214 high dose; Risperidone; Placebo

Mitsubishi Tanabe Pharma Corporation - Recruiting 20 years to 64 years.
- A Double-Blind, Placebo-Controlled Study of MP-214 in Patients With Schizophrenia.
MP-214 low dose; MP-214 middle dose; MP-214 high dose; Risperidone; Placebo

Schizophrenia Clinical Trial using Paliperidone Palmitate

Xian-Janssen Pharmaceutical Ltd. - Recruiting 18 years to 65 years.
- Safety and Effectiveness of Paliperidone Palmitate in 25-week Treatment on Chinese Patients With Schizophrenia: an Open-label, Single-arm, Multicenter Prospective Study.
Paliperidone Palmitate

Schizophrenia Clinical Trial using MP-214 low dose; MP-214 high dose; Risperidone

Mitsubishi Tanabe Pharma Corporation - Recruiting 20 years to 74 years.
- A Long-term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia.
MP-214 low dose; MP-214 high dose; Risperidone

Schizophrenia, or Schizoaffective Disorder Clinical Trial using Modafinil; Functional MRI; Neuropsychological Testing

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 50 years.
- Randomized, Double-Blinded, Placebo Controlled Study of the Effects of Modafinil on Cognitive Function in Patients With Schizophrenia and Normal Controls Based on COMT Genotype.
Modafinil; Functional MRI; Neuropsychological Testing

Schizophrenia Clinical Trial using Brain Fitness Program (BFP); Cognitive Package (Cogpack); Commercial Computer Games (CCG)

Department of Veterans Affairs - Recruiting 25 years to 55 years.
- Evaluating Two Types of Cognitive Training in Veterans With Schizophrenia.
Brain Fitness Program (BFP); Cognitive Package (Cogpack); Commercial Computer Games (CCG)

Healthy, or Schizophrenia Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 55 years.
- Integrating EEG/MEG and fMRI: Activity Correlation Between Frontal and Temporal Lobe Structures in Schizophrenic Patients, Their Siblings and Unrelated Normal Volunteers.

Schizophrenia Clinical Trial using 3-2,4 dimethoxybenzylidene 75 or 150 mg bid; Placebo

Department of Veterans Affairs - Recruiting 18 years to 65 years.
- Phase 2 Trial of 3-2,4 Dimethoxybenzylidene Anabaseine in Schizophrenia.
3-2,4 dimethoxybenzylidene 75 or 150 mg bid; Placebo

Schizophrenia, Substance Abuse, Cocaine Abuse, or Tobacco Use Dis Clinical Trial using Various Screening psychiatric and medical assessments

University of Maryland - Recruiting 18 years to 64 years.
- Screening Protocol for the Evaluation of Research Participants.
Various Screening psychiatric and medical assessments

Schizophrenia Clinical Trial using Paliperidone palmitate

Janssen-Cilag Farmaceutica Ltda. - Recruiting 18 years to 49 years.
- Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate - A Pilot Study.
Paliperidone palmitate

Schizophrenia, or Nicotine Addiction Clinical Trial using Repetitive Transcranial Magnetic Stimulation (rTMS); Sham Repetitive Transcranial Stimulation (rTMS)

Centre for Addiction and Mental Health - Recruiting 18 years to 55 years.
- Effects of Repetitive Transcranial Magnetic Stimulation on Cigarette Smoking and Cognitive Function in Smokers With and Without Schizophrenia.
Repetitive Transcranial Magnetic Stimulation (rTMS); Sham Repetitive Transcranial Stimulation (rTMS)

Healthy, Mood Disorder, Parkinson's Disease, or Schizophrenia Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Structural and Functional Imaging of Neuropsychiatric Patients and Normal Volunteers With 3.0 Tesla MRI and Magnetoencephalography.

Schizophrenia Clinical Trial using EEG

University Hospital, Strasbourg, France - Recruiting 18 years to 50 years.
- Relating the 'Experienced Present' With the Mechanisms of Neuronal Function: A Comparative Study in Patients With Schizophrenia and Healthy Controls Using Psychophysical and Neurophysiological Methods.
EEG

Schizophrenia Clinical Trial using eszopiclone; placebo

Massachusetts General Hospital - Recruiting 18 years to 45 years.
- Sleep-dependent Memory Processing in Schizophrenia.
eszopiclone; placebo

Schizophrenia, Schizophrenic Disorder, Hyperprolactinemia, or Hyp Clinical Trial using PGD granules; Placebo

The University of Hong Kong - Recruiting 18 years to 60 years.
- The Herbal Medicine Peony-Glycyrrhiza Decoction (PGD) as an Adjunctive Therapy to Treat Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia: a Double-blind, Randomized, Placebo-controlled Study.
PGD granules; Placebo

Schizophrenia, or Schizoaffective Disorder Clinical Trial using Intranasal Oxytocin Spray

University of North Carolina, Chapel Hill - Recruiting 18 years to 65 years.
- Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia.
Intranasal Oxytocin Spray

Schizophrenia and Schizoaffective Disorder, or Tardive Dyskinesia Clinical Trial using D-serine

Herzog Hospital - Recruiting 18 years to 70 years.
- D-SERINE TREATMENT FOR TARDIVE DYSKINESIA.
D-serine

Schizophrenia Clinical Trial using Brain Fitness & Brain Training- Posit Science; Facial Affect Training- FAT

University of Konstanz - Recruiting 18 years to 60 years.
- Training-induced Cerebral Reorganization in Schizophrenia.
Brain Fitness & Brain Training- Posit Science; Facial Affect Training- FAT

Schizophrenia, or Psychotic Disorders Clinical Trial using Theta Burst Transcranial Magnetic Stimulation

UMC Utrecht - Recruiting 18 years or older.
- Theta Burst Transcranial Magnetic Stimulation as Treatment for Auditory Verbal Hallucinations; a Placebo-controlled Trail.
Theta Burst Transcranial Magnetic Stimulation

Schizophrenia, or Schizoaffective Disorder Clinical Trial using Cannabidiol; Placebo

Yale University - Recruiting 18 years to 65 years.
- Cannabinoid Receptor Antagonist Treatment of Cognitive Dysfunction in Schizophrenia.
Cannabidiol; Placebo

Autism Spectrum Disorders, or Schizophrenia Clinical Trial using Neuropsychological evaluation

University Hospital, Strasbourg, France - Recruiting 7 years to 55 years.
- Visual Exploration and Attention : Studies in Patients With Schizophrenia and Autism Spectrum Disorders.
Neuropsychological evaluation

Schizophrenia, Schizoaffective Disorder, or Schizophreniform Diso Clinical Trial

University of Maryland - Recruiting 14 years to 62 years.
- Neural Oscillations as Genetic and Functional Biomarkers in Normal and Disease States.

Schizophrenia Clinical Trial using Minocycline; placebo

Shalvata Mental Health Center - Recruiting 20 years to 65 years.
- .
Minocycline; placebo

Schizophrenia Clinical Trial using H1 deep TMS coil; Sham

Shalvata Mental Health Center - Recruiting 18 years to 65 years.
- A Double Blind Randomized Controlled Trial to Explore the Tolerability, Safety and Efficacy of the H-Coil Deep Transcranial Magnetic Stimulation (TMS) in Subjects With Negative Symptoms and Cognitive Deficits of Schizophrenia.
H1 deep TMS coil; Sham

Schizophrenia, Schizoaffective Disorder, Major Depression, Bipola Clinical Trial using Eicosapentaenoic acid (omega-3 fatty acid); Placebo

University of Pittsburgh - Recruiting 18 years or older.
- CAD Risk in Schizophrenia: Effect of Omega-3 Fatty Acid Supplementation.
Eicosapentaenoic acid (omega-3 fatty acid); Placebo

Schizophrenia Clinical Trial using Tiagabine; Placebo

Beth Israel Deaconess Medical Center - Recruiting 18 years to 25 years.
- Addition of Tiagabine to Second-Generation Antipsychotics in the Treatment of Recent-Onset Schizophrenia by Modification of Developmental Reorganization of the Prefrontal Cortex.
Tiagabine; Placebo

Schizophrenia, or Negative Symptoms Clinical Trial using mirtazapine and folic acid; mirtazapine, folic acid placebo; mirtazapine placebo, folic acid; mirtazapine placebo, folic acid placebo

Capital Medical University - Recruiting 18 years to 70 years.
- Multicentre Randomised Double-blind, Placebo-controlled 2x2 Factorial Trial Investigating the Effects of Adding Mirtazapine and Folic Acid to Existing Therapy for Patients With Schizophrenia.
mirtazapine and folic acid; mirtazapine, folic acid placebo; mirtazapine placebo, folic acid; mirtazapine placebo, folic acid placebo

Schizophrenia Clinical Trial using Amantadine; Placebo

Hospital de Clinicas de Porto Alegre - Recruiting 18 years to 60 years.
- A Double-blind, Randomized, Placebo-controlled Trial With Amantadine as Adjunctive Therapy to Antipsychotics in Schizophrenia.
Amantadine; Placebo

Schizophrenia, or Schizoaffective Disorder Clinical Trial using long-acting injectable risperidone; long acting injectable risperidone

Vanderbilt University - Recruiting 18 years to 65 years.
- High Dose Risperidone Consta for Patients With Schizophrenia With Unsatisfactory Response to Standard Dose Risperidone or Long-Acting Injectable.
long-acting injectable risperidone; long acting injectable risperidone

Schizophrenia, Schizoaffective Disorder, Psychosis Not Otherwise Clinical Trial using Ondansetron; Simvastatin; Placebo

Pakistan Institute of Learning and Living - Recruiting 18 years to 65 years.
- Study of Role of Anti-Inflammatory Agents in Patients With Schizophrenia.
Ondansetron; Simvastatin; Placebo

Smoking Cessation, or Schizophrenia Clinical Trial using Tropisetron; Placebo; Risperidone

National Institute of Mental Health (NIMH) - Recruiting 18 years to 64 years.
- Tropisetron With Risperidone for Schizophrenia.
Tropisetron; Placebo; Risperidone

Psychotic Disorders, Schizophrenia, Schizoaffective Disorder, Del Clinical Trial using modified cognitive behavioural therapy (mCBT)

University of Cologne - Recruiting 14 years to 18 years.
- Development and Pilot Evaluation of Modified Cognitive Behavioural Therapy for Adolescents With Early Onset Psychosis.
modified cognitive behavioural therapy (mCBT)

Schizophrenia, Schizoaffective Disorder, or Schizophreniform Diso Clinical Trial using Estradiol

Bayside Health - Recruiting 18 years to 45 years.
- Double Blind Study of Estradiol Plus Neuroleptic Versus Placebo Plus Neuroleptic in the Treatment of Psychotic Symptoms in Women With Schizophrenia.
Estradiol

Schizophrenia Clinical Trial using reboxetine adjuvant therapy

Abarbanel Mental Health Center - Recruiting 18 years to 65 years.
- Phase 1 Study of Reboxetine Adjuvant Therapy and Cognitive and Behavioral Measures.
reboxetine adjuvant therapy